0
Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec – A Sweet Life
![]() BusinessWeek |
Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec
A Sweet Life by the US Food and Drug Administration. These new insulin analogs have been developed for the treatment of people with type 1 and type 2 diabetes. As with the European applications submitted on September 26, the US filings are based on results from the … Novo Nordisk Files For US Approval Of New Insulin Drugs Danish Novo Nordisk applies for approval of two diabetes drugs in USA Upscale Insulin Gets a Shot |






